About Asabys Partners
Asabys Partners is a venture capital firm founded in 2019. It is primarily based out of Barcelona, Spain. As of Jun 2026, Asabys Partners is an active investor, having invested in 22 companies, with 2 new investments in the last 12 months. It primarily invests in Seed round in Spain based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series B round of Ona Therapeutics Overall, Asabys Partners portfolio has seen 1 IPO and 3 acquisitions, namely Koa Health, AgomAb Therapeutics and Cara Care. A lot of funds co-invest with Asabys Partners, with names like Wellington Partners Venture Capital sharing a substantial percentage of its portfolio. Asabys Partners has team of 10 people including 5 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Rounds of Entry
Series A, Seed & 3 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Asabys Partners' List of Top Investments
Asabys Partners has a portfolio of 22 companies. Their most notable investments are in Amelia Virtual Care and XRHealth.Their portfolio spans across Spain, Belgium, France and 4 more locations. They have invested in Life Sciences, HealthTech, High Tech and 3 other sectors, across stages such as Series A, Seed and 3 more. Here is the list of top investments by Asabys Partners:Sidekick is a gamified social health platform for providers, insurers, lifestyle coaches, and employers for the purpose of checking the health and wellness of their members. The platform provides employees with health-improving tasks to motivate and engage people towards a healthy lifestyle in nutrition, physical activity, and mental exercise categories. Sidekick motivates users to improve their diet, get active, de-stress via meditating, and keep a track of body vitals along with providing people to communicate, collaborate, and compete with friends and colleagues. The app collects data from wearable devices and user input rewarding users for health-improving activities. The current programs targets solutions for employee wellness and diabetes prevention programs.
Key facts about SidekickHealth
- Founded Year: 2013
- Location: Palo Alto (United States)
- Stage: Series B
- Total Funding till date: $76.5M
- Employee Count: 237 as on May 31, 2026
- Investors: Novator, Novator Partners and 7 Others
- Latest Funding Round: Venture Debt, May 01, 2025, $*****
- Highlight: Editors' Pick
2. XRHealth
VR-based platform to transform patient care and rehabilitation. It uses proprietary virtual and augmented reality technology and data analytics. Its virtual clinics host real and virtual environments, games, and exercises that treat various motor, cognitive, and physical symptoms.
Key facts about XRHealth
- Founded Year: 2016
- Location: Brookline (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2021
- Valuation: $*****
- Stage: Series B
- Total Funding till date: $40M
- Employee Count: 122 as on May 31, 2026
- Investors: Flint Capital, Florida-Israel Business Accelerator and 14 Others
- Latest Funding Round: Series B, Jan 09, 2024, $*****
- Highlight: Editors' Pick
3. Koa Health
Provider of digitally-enabled mental health therapies and platform solutions. It offers clinically validated treatments for anxiety, PTSD, and social anxiety in children, teens, and adults. The solutions are designed for use by healthcare providers and families, facilitating collaboration towards recovery. A unified platform, provides access to support across the mental health continuum, encompassing lifestyle, prevention, and therapy. It also offers data and analytics to support population level insights. The approach prioritizes prevention and utilizes evidence based care. Healthcare providers use the platform to provide patients with mobile assisted tools for teleconsultation, mental health activities, stress management, and more. Mobile first treatments and progress-tracking tools are built by the company for the payers to monitor clients health and condition.
Key facts about Koa Health
- Founded Year: 2016
- Location: London (United Kingdom)
- Annual Revenue: £0 - £1M as on Dec 31, 2023
- Stage: Acquired
- Total Funding till date: $36M
- Employee Count: 48 as on May 31, 2026
- Investors: Mundi Ventures, AA Sons and 9 Others
- Latest Funding Round: Series A, Oct 2020, $*****
- Highlight: Acquired
Developer of implantable neurotechnology for decoding and modulating brain activity. The company focuses on creating bi-directional, high-resolution brain-computer interfaces. These interfaces enable real-time smart neural decoding and modulation in closed loop. The company's platform combines hardware and data analytics to personalize therapy.
Key facts about INBRAIN Neuroelectronics
- Founded Year: 2019
- Location: Barcelona (Spain)
- Stage: Series B
- Total Funding till date: $82.8M
- Employee Count: 119 as on May 31, 2026
- Investors: TruVenturo, European Investment Bank and 16 Others
- Latest Funding Round: Grant (prize money), May 09, 2025, $*****
- Highlight: Editors' Pick
Developer of monoclonal antibody molecules for multiple disorders. The company has developed the monoclonal antibody molecules called agomAbs which stimulates the molecular and cellular repair mechanisms. It helps in organ function for patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases.
Key facts about AgomAb Therapeutics
- Founded Year: 2017
- Location: Ghent (Belgium)
- Stage: Public
- Total Funding till date: $327M
- Employee Count: 74 as on May 31, 2026
- Investors: Fidelity Investments, Sanofi and 16 Others
- Latest Funding Round: Series D, Oct 25, 2024, $*****
- Highlight: Public
Asabys Partners' Year-on-Year Investment Trends
Asabys Partners has invested in 22 companies over the last 7 years, with an average of 2 new investments annually in the last 5 years. In 2025, it made 7 investments, while as of Jun 2026, it has made 1 investment in this year. Its most recent first time investment was in Qida and most recent follow-on round was in Ona Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 3 | 4 | 7 |
2024 | 2 | 2 | 4 |
2023 | 4 | 0 | 4 |
2022 | 1 | 3 | 4 |
2021 | 0 | 1 | 1 |
2020 | 7 | 1 | 8 |
2019 | 4 | 0 | 4 |
Asabys Partners' Investments by Stage
Asabys Partners has made 7 investments in Series A stage with an average round size of $22.2M, 6 investments in Seed stage with an average round size of $5.89M, 4 investments in Series B stage with an average round size of $21.7M, 3 investments in Series C stage with an average round size of $24.1M and 1 investment in Series E stage with an average round size of $21.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 7 |
Seed | 6 |
Series B | 4 |
Series C | 3 |
Series E | 1 |
Note: We have considered here, only first round of investments
Asabys Partners' Investments by Sector
Asabys Partners has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Enterprise Applications, High Tech and Vertical SaaS. Notably, it has invested in 21 Tech companies, 20 Enterprise (B2B) companies, 7 Tech hardware companies and at least 6 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 15 |
HealthTech | 7 |
Enterprise Applications | 4 |
High Tech | 4 |
Vertical SaaS | 3 |
Others | 6 |
Note: We have considered here, only first round of investments
Asabys Partners' Investments by Geography
Asabys Partners has made most investments in Spain (12), followed by Belgium where it has made 2 investments.Country | No. of Investments |
|---|---|
Spain | 12 |
Belgium | 2 |
France | 2 |
United States | 2 |
Germany | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
Asabys Partners' recent investments
Asabys Partners has made 1 investments in 2026 so far - Ona Therapeutics.Here are the most recent investments by Asabys Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 04, 2026 | Spain | Series B | 4887 | ||
Nov 04, 2025 | Spain | Series C | 4790 | [+6] | |
Oct 09, 2025 | Spain | Series A | 1843 | [+3] | |
Sep 10, 2025 | France | Series C | 2533 | [+4] | |
Jun 11, 2025 | Spain | Series B | 8563 | [+7] |
IPOs and Publicly Listed companies in Asabys Partners' Portfolio
1 of Asabys Partners' portfolio company became public - AgomAb Therapeutics. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2026 at marketcap of $780MHere are Asabys Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 06, 2026 | Jul 13, 2022 | Series B | 1360 |
Acquired companies in Asabys Partners' Portfolio
3 companies from Asabys Partners' portfolio have been acquired. The most recent acquisition was Koa Health in Jun 2026 by PsychPlus for $*****.Here are Asabys Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 23, 2026 | Oct 2020 | Series A | 5502 | |
Dec 11, 2024 | Jun 18, 2019 | Series A | 4368 | |
Oct 28, 2021 | Jul 07, 2020 | Seed | 3676 |
_1578046162242.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of Asabys Partners
Asabys Partners has a team of 10 members including 5 Partners and 1 Principal located in Spain and United States. Asabys Partners' team does not sit on the board of any company as of now.Here is a list of all team members in Asabys Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Barcelona | - | ||
Partner | Barcelona | - | ||
Partner | Sitges | - | ||
Partner | Barcelona | - | ||
Partner | - | - | - | |
Principal | New York | - |
Co-investors of Asabys Partners
Over the past 7 years, 154 investors have co-invested in Asabys Partners's portfolio companies. This includes funds and angels.
- Invested before Asabys Partners: Europa, EIC Fund and 63 others have invested in rounds before Asabys Partners. There are 4 companies where Europa has invested before Asabys Partners and 2 companies where EIC Fund has invested before Asabys Partners.
- Top Co-investors of Asabys Partners: 45 investors entered a company along with Asabys Partners. These include investors like Wellington Partners Venture Capital (2 companies).
- Invested after Asabys Partners: A total of 44 investors have invested in Asabys Partners's portfolio after their investments. Top Investors include CDTI (3 companies), European Investment Bank (2 companies) and EIC Fund (2 companies).
Recent News related to Asabys Partners
•
Ona Therapeutics Secures 74 Million Euros to Advance Oncology Drug DevelopmentExpansion•Jun 04, 2026•Ona Therapeutics, Columbus Venture Partners, Merieux Equity Partners, Cuatrecasas and 6 others
•
Asabys bets on biotechnology with a fund of up to 120 million eurosEl Referente•May 19, 2026•Asabys Partners
•
BStartup10 leads an investment round in Miramoon PharmaWebcapitalriesgo•Nov 18, 2025•Miramoon Pharma, Asabys Partners, Alta Life Sciences, Columbus Venture Partners
•
Qida, Spain’s ‘Amazon for aging care,’ lands €37M to expand its digital home care networkTech Funding News•Nov 05, 2025•Endeavor, Asabys Partners, Qida, COFIDES and 4 others
•
Qida closes €37M round led by QuadrilleWebcapitalriesgo•Nov 04, 2025•Asabys Partners, Qida, Quadrille Capital, Cofides and 4 others
•
•
Asabys Partners Leads €10 Million Extension of SafeHeal's Series C FinancingBenzinga•Sep 10, 2025•SafeHeal, Asabys Partners, Gideon Strategic Partners, Sofinnova Partners and 1 other
•
deepull Raises €50M in Series C FinancingFinSMEs•Apr 30, 2025•DeepUll, Columbus Venture Partners, Panakes Partners, Merieux Equity Partners and 7 others
•
Quibim Announces New Board of Directors To Promote Growth And Strategic ExpansionBusiness Wire•Apr 08, 2025•Quibim, Amadeus Capital, Partech Partners, Asabys Partners and 2 others
•
Asabys Reinvests in Belgian Augustine, Which Raises €78 MillionExpansion•Mar 24, 2025•Asabys Partners, Augustine Therapeutics, Novo Holdings, Jeito and 7 others
